Official Title
Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA
Brief Title
Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA
Protocol ID
NCT04104633
Lead Sponsor
Centre Hospitalier Henri Duffaut - Avignon
Brief Summary
There are several types of circulating DNA: DNA from patient's existing cells, foetal DNA
in the case of pregnant woman, and tumoral DNA in the case of patients with cancer. These
circulating tumoral DNA (ctDNA) can be obtained from a blood test called liquid biopsy
and be detected by the latest generation of very high throughput sequencers with the
Massive Parallel Sequencing technique (MPS).
This study focus on using this technique on breast and colorectal cancers in which no
analysis of CNV (tumor origin marker) with this technique has been performed yet. It is a
prospective, pilot, monocentric, feasibility study on genomic profile. The study aim is
to show the possibility to realize in a reproductive way a molecular karyotype on ctDNA
with the MPS approach from a liquid biopsy taken from patients with cancer and to compare
this profile with the one obtained by CGH array (Comparative Genomic Hybridization) from
primitive tumor.
Study Period
-
Enrollment Count
18 participants
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years
- Signed consent
- Women with invasive breast carcinoma, NOS, with a radiologically measurable tumor of
more than 10 mm (stade I to III)
- Patients with invasive colorectal adenocarcinoma with a radiologically measurable
tumor of more than 10 mm (stade I to III)
- Patients who primary surgery is planned
Exclusion Criteria:
- Neoadjuvant chemotherapy or neoadjuvant radiotherapy
- Other cancer
- BMI > 30
- Pregnant woman
- Patients under protective administration or deprived of liberty
Filters
Breast Cancer
Colo-rectal Cancer
NA
COMPLETED
ADULT
OLDER_ADULT